Try our Advanced Search for more refined results
Life Sciences
- 
									October 03, 2025
									Benzene At NC BASF Plant Caused Cancer, Ex-Worker SaysA former worker at a North Carolina vitamin plant is suing BASF Corp. and affiliates of Takeda America Holdings Inc. in North Carolina federal court, alleging BASF exposed her to benzene, resulting in her developing cancer later in life. 
- 
									October 03, 2025
									The Roberts Court At 20: How The Chief Is Reshaping AmericaTwenty years after John Roberts became the 17th chief justice of the United States, he faces a U.S. Supreme Court term that's looking transformative for the country and its institutions. How Justice Roberts and his colleagues navigate mounting distrust in the judiciary and set the boundaries of presidential authority appear increasingly likely to define his time leading the court. 
- 
									October 03, 2025
									Stryker Gets Fed. Circ. To Ax Bone Fusion Patent ClaimsThe Federal Circuit on Friday reversed the Patent Trial and Appeal Board's findings that Stryker failed to show that certain claims were anticipated in a trio of OsteoMed patents relating to ways to secure bones together. 
- 
									October 02, 2025
									PTAB Condemns Bristol-Myers' 'Whac-A-Mole Strategy'The Patent Trial and Appeal Board has ended Amgen Inc.'s challenge to a now-disclaimed patent covering Bristol-Myers Squibb Co.'s blockbuster cancer drug Opdivo, and denied Bristol-Myers' request to pursue a replacement patent. 
- 
									October 02, 2025
									FDA OKs New Generic Abortion Pill, Drawing Conservative IreThe U.S. Food and Drug Administration has approved a second generic version of the abortion medication mifepristone, prompting outrage from anti-abortion groups and conservative politicians. 
- 
									October 02, 2025
									Feds Eye Partial Pretrial Ruling In Regeneron FCA CaseThe government has urged a Massachusetts federal judge to rule that Regeneron Pharmaceuticals "naturally or foreseeably" caused providers to present false claims for its macular degeneration drug Eylea, arguing that it does not need to prove the tougher "but-for causation" standard for its theory of false certification. 
- 
									October 02, 2025
									NC Chief Judge Scolds Medical Supply Co.'s 'Rude' DemandA North Carolina federal judge on Wednesday threw out a medical supply company's suit over COVID-19 test kit profits based on the Chinese citizenship of one party, adding that the plaintiff's impatience with the court amid a judge shortage was "rude." 
- 
									October 02, 2025
									Peach State Panel Tosses $500K Verdict In Peach Picking SpatThe Georgia Court of Appeals ordered a new trial in a case where a jury awarded $500,000 worth of punitive damages to a peach grower who said his crop was ruined by another farmer, ruling that inadmissible evidence about their settlement talks was "likely significant" in securing the verdict. 
- 
									October 02, 2025
									AstraZeneca Asks Judge To Block Colorado's 340B Drug LawAstraZeneca urged a Colorado federal judge on Wednesday to block the enforcement of a recently enacted state law that aims to extend a federal drug discount program to certain pharmacies, saying the Colorado law is costly for manufacturers and preempted by federal law. 
- 
									October 02, 2025
									Bain Inside Trade Claims Advance In Del. Cerevel Sale SuitDelaware's Court of Chancery on Thursday kept alive a pension funds suit alleging that private equity firm Bain Capital Investors LLC and others traded on inside information in the run-up to a secondary sale ahead of biopharmaceutical venture Cerevel Therapeutics Holdings Inc.'s $8.7 billion acquisition by AbbVie. 
- 
									October 02, 2025
									NC State Demands Monsanto Pay For 'Toxic' PCB CleanupNorth Carolina State University is looking to hold Monsanto Co. accountable for the contamination of one of its buildings, accusing the former agrochemical giant in North Carolina state court of marketing a chemical used in building materials despite knowing it was toxic. 
- 
									October 02, 2025
									Fed. Circ. Affirms Cutting $10M Med Device IP Verdict To $1The Federal Circuit on Thursday said a lower court had properly reduced to $1 what had been a $10 million patent infringement verdict against Intuitive Surgical Inc., saying any amount between the two figures "would require improper guesswork," given the lack of evidence on damages. 
- 
									October 02, 2025
									Many Cos. Not Ready For National Security Risks, Report SaysAt least a third of U.S. companies aren't fully prepared to address key national security compliance risks they face, and the C-suite often isn't aligned with its in-house counsel as to who is primarily responsible for those efforts, according to a new survey from Eversheds Sutherland. 
- 
									October 02, 2025
									J&J Must Pay $10M In Punitive Damages After Asbestos LossA Connecticut state court judge has hit Johnson & Johnson with $10 million in punitive damages after a jury sided with a builder who alleged the company's baby powder caused his terminal cancer, adding the amount to an existing $15 million verdict. 
- 
									October 02, 2025
									Singaporean Biotech To Go Public Via $1.5B SPAC MergerSingapore-based biotechnology company Nanyang Biologics Pte. Ltd. on Thursday announced plans to go public in the U.S. by merging with special purpose acquisition company RF Acquisition Corp. II in a deal that gives the biotech a pre-transaction equity value of $1.5 billion. 
- 
									October 02, 2025
									Court Warned Of Harm From Delaying Medical Device MergerA D.C. federal court refused to pause the Federal Trade Commission's case challenging Edwards Lifesciences Corp.'s planned acquisition of JenaValve Technology Inc. during the government shutdown after the companies argued that "time is of the essence" for a new lifesaving medical device. 
- 
									October 01, 2025
									Squires Jumps Right Into Patent Eligibility ReformU.S. Patent and Trademark Office Director John Squires used his first week at the agency to make bold statements about what should be eligible for patenting, with patent owners celebrating his support of diagnostics, crypto and machine learning technologies. 
- 
									October 01, 2025
									Eli Lilly's Drug Suit Slammed As 'Anti-Competitive' MoveEli Lilly and Co.'s lawsuit accusing a compounding pharmacy of unlawfully selling untested weight loss drugs should be tossed because the drugmaker didn't show its advertising was deceptive or harmful, the defendant told a Texas federal court this week. 
- 
									October 01, 2025
									EPA Seeks Dismissal Of Flint Bellwethers, Says It's Not LiableThe U.S. Environmental Protection Agency has defended its timing of using its authority to issue a Safe Drinking Water Act order regarding lead in the city of Flint's water, urging a Michigan federal judge to dismiss claims from bellwether plaintiffs who alleged the agency was negligent in its response to the crisis. 
- 
									October 01, 2025
									Inventor's $11M Award Slashed To $5M Over Pet Device IPA New Jersey federal judge has hit two pet supply companies with a $5 million damages bill for misappropriating a woman's idea for a skin medicine applicator for dogs and cats, more than four years after the Federal Circuit faulted the original $11 million award in the long-running case. 
- 
									October 01, 2025
									Medtronic Knocks Out Investor Suit Over Insulin Pump IssuesMedical device manufacturer Medtronic PLC has escaped proposed investor class action claims it concealed issues affecting a certain insulin pump it makes, hurting investors after its trading prices fell when the company disclosed it had received a related warning letter from the U.S. Food and Drug Administration. 
- 
									October 01, 2025
									Monthly Merger Review SnapshotThe Federal Trade Commission put the final tweaks on its deal allowing a $13.5 billion merger of marketing companies to move ahead and pushed its bid to block a merger in the medical device coatings industry, while U.K. enforcers launched a number of merger probes. 
- 
									October 01, 2025
									Texas Judge Sends Mifepristone Challenge To Missouri CourtA closely watched challenge to federal approvals for the abortion medication mifepristone is moving from Texas to Missouri after a federal judge found the plaintiffs remaining in the litigation have no connection to the Lone Star State. 
- 
									October 01, 2025
									Ga. Atty DQ'd From 'Extremely Weird' Pharma Fraud CaseA Georgia federal judge said Wednesday she intends to disqualify a prominent defense attorney from representing a man charged with lying to investigators amid a criminal fraud probe into his employer, Hi-Tech Pharmaceuticals Inc., but would allow the company to continue footing his legal bills as he seeks new counsel. 
- 
									October 01, 2025
									Cozen O'Connor Adds Healthcare Litigator To Philly OfficeAn attorney with more than three decades of experience representing healthcare providers in litigation matters has recently moved his practice to Cozen O'Connor's Philadelphia shop. 
Expert Analysis
- 
								Series Creating Botanical Art Makes Me A Better Lawyer  Pressing and framing plants that I grow has shown me that pursuing an endeavor that brings you joy can lead to surprising benefits for a legal career, including mental clarity, perspective and even a bit of humility, says Douglas Selph at Morris Manning. 
- 
								Opinion The Legal Education Status Quo Is No Longer Tenable  As underscored by the fallout from California’s February bar exam, legal education and licensure are tethered to outdated systems, and the industry must implement several key reforms to remain relevant and responsive to 21st century legal needs, says Matthew Nehmer at The Colleges of Law. 
- 
								
								2nd Circ. Reinforces Consensus On Vacating Foreign Awards  In Molecular Dynamics v. Spectrum Dynamics Medical, the Second Circuit recently affirmed that federal district courts do not possess subject matter jurisdiction to vacate foreign arbitral awards, strengthening this consensus across the circuits most active in recognition and enforcement actions, says Ed Mullins at Reed Smith. 
- 
								
								E-Discovery Quarterly: Rulings On Relevance Redactions  In recent cases addressing redactions that parties sought to apply based on the relevance of information — as opposed to considerations of privilege — courts have generally limited a party’s ability to withhold nonresponsive or irrelevant material, providing a few lessons for discovery strategy, say attorneys at Sidley. 
- 
								
								How DOJ's New Data Security Rules Leave HIPAA In The Dust  The U.S. Department of Justice's recently effective data security requirements carry profound implications for how healthcare providers collect, store, share and use data — and approach vendor oversight — that go far beyond the Health Insurance Portability and Accountability Act, say attorneys at Nelson Mullins. 
- 
								Opinion Section 1983 Has Promise After End Of Nationwide Injunctions.jpg)  After the U.S. Supreme Court recently struck down the practice of nationwide injunctions in Trump v. Casa, Section 1983 civil rights suits can provide a better pathway to hold the government accountable — but this will require reforms to qualified immunity, says Marc Levin at the Council on Criminal Justice. 
- 
								
								Trump's 2nd Term Puts Merger Remedies Back On The Table.jpg)  In contrast with the Biden administration, the second Trump administration has signaled a renewed willingness to resolve merger enforcement concerns through remedies from the outset, particularly when the proposed fix is structural, clearly addresses the harm and does not require burdensome oversight, say attorneys at Cooley. 
- 
								
								Patent Ambiguity Persists After Justices Nix Eligibility Appeal  The Supreme Court recently declined to revisit the contentious framework governing patent eligibility by denying certiorari in Audio Evolution Diagnostics v. U.S., suggesting a necessary recalibration of both patent application and litigation strategies, say attorneys at Skadden. 
- 
								
								Texas Med Spas Must Prepare For 2 New State Laws  Two new laws in Texas — regulating elective intravenous therapy and reforming healthcare noncompetes — mark a pivotal shift in the regulatory framework for medical spas in the state, which must proactively adapt their operations and contractual practices, says Brad Cook at Munsch Hardt. 
- 
								
								Fed. Circ. In June: Transitional Phrases In Patent Claims  The Federal Circuit's recent decision in Eye Therapies v. Slayback Pharma takes on the rarely addressed topic of transitional phrases in patent claims, providing some useful lessons regarding restating claim language and broadly distinguishing prior art, say attorneys at Knobbe Martens. 
- 
								Series Playing Soccer Makes Me A Better Lawyer  Soccer has become a key contributor to how I approach my work, and the lessons I’ve learned on the pitch about leadership, adaptability, resilience and communication make me better at what I do every day in my legal career, says Whitney O’Byrne at MoFo. 
- 
								
								Strategies For Cos. Navigating US-Indian Pharma Partnerships  Recent policy adjustments implemented by the U.S. government present both new opportunities and heightened regulatory scrutiny for the Indian life sciences industry, amplifying the importance of collaboration between the Indian and U.S. pharmaceutical sectors, say Bryant Godfrey at Foley Hoag and Jashaswi Ghosh at Holon Law Partners. 
- 
								
								DOJ-HHS Collab Crystallizes Focus On Health Enforcement  The recently announced partnership between the U.S. Department of Justice and U.S. Department of Health and Human Services to combat False Claims Act violations, following a multiyear trend of high-dollar DOJ recoveries, signals a long-term enforcement horizon with major implications for healthcare entities and whistleblowers, say attorneys at RJO. 
- 
								Series Law School's Missed Lessons: Learning From Failure  While law school often focuses on the importance of precision, correctness and perfection, mistakes are inevitable in real-world practice — but failure is not the opposite of progress, and real talent comes from the ability to recover, rethink and reshape, says Brooke Pauley at Tucker Ellis. 
- 
								
								23andMe Fine Signals ICO's New GDPR Enforcement Focus  Many of the cybersecurity failures identified by the Information Commissioner’s Office in its investigation of 23andMe, recently resulting in a £2.3 million fine, were basic lapses, but the ICO's focus on several new U.K. General Data Protection Regulation considerations will likely carry into the future, say lawyers at Womble Bond.